VSIG8

VSIG8 is a functional ligand of the immune checkpoint receptor VISTA that operates in a co-inhibitory pathway suppressing T cell function (PMID:35404016). VSIG8 binds VISTA directly with a Kd of ~1.58 µM through a defined interface, since alanine substitution of the VISTA binding site abolishes the interaction (PMID:35404016). Engagement is functionally consequential: VSIG8 protein lowers IL-2 production in VISTA-overexpressing cells but raises IL-2 in VISTA-deficient cells, establishing that its T cell-inhibitory effect is strictly VISTA-dependent (PMID:35404016). An earlier ELISA screen did not detect VSIG8/VISTA binding under conditions where VSIG-3/IGSF11 bound VISTA, indicating the interaction is assay-sensitive (PMID:30220083). Beyond this VISTA interaction, no further mechanistic detail for VSIG8 has been characterized in the available corpus.

1. 2018 Medium

   Testing whether VSIG8 was among the VISTA-binding partners, an ELISA screen returned a negative result, leaving the question of a VSIG8/VISTA interaction unresolved under those conditions.

   Evidence Functional ELISA binding screening assay comparing VSIG8 to VSIG-3/IGSF11 for VISTA binding

   PMID:30220083

   Open questions at the time

   • Single assay format may miss low-affinity or conformation-dependent binding
   • No orthogonal binding method or genetic validation
   • Did not test functional consequences
2. 2022 High

   Establishing VSIG8 as a bona fide VISTA ligand resolved the earlier ambiguity by demonstrating direct micromolar-affinity binding through a defined interface and a VISTA-dependent suppression of T cell IL-2 output.

   Evidence ELISA, MST, Co-IP, alanine-scanning mutagenesis of the VISTA binding site, and IL-2 cytokine assays in VISTA-overexpressing and VISTA-knockout cells

   PMID:35404016

   Open questions at the time

   • Work performed in a single lab without independent replication
   • Structural model of the VSIG8/VISTA interface not determined
   • Directionality of signaling (which partner transduces the inhibitory signal) not dissected in primary T cells

• Whether VSIG8 engages additional receptors, its expression pattern across cell types, and its role in vivo remain unaddressed in the available corpus.
• No in vivo or disease-model evidence for VSIG8/VISTA axis
• No structural determination of the binding interface
• No characterization of VSIG8 expression or regulation